$LPCN
Lipocine Inc.

2014 Q4 Form 10-Q Financial Statement

#000114420414066218 Filed on November 10, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q4
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.170M $870.0K $1.030M
YoY Change 13.59% -26.27%
% of Gross Profit
Research & Development $2.890M $3.247M $2.460M
YoY Change 17.48% 106.92%
% of Gross Profit
Depreciation & Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $4.060M $4.118M $3.500M
YoY Change 16.0% 16.15%
Operating Profit -$4.118M
YoY Change 16.15%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $20.00K $20.00K $20.00K
YoY Change 0.0% 0.0%
Pretax Income -$4.040M -$4.094M -$4.390M
YoY Change -7.97% 15.96%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$4.040M -$4.094M -$4.390M
YoY Change -7.97% 17.8%
Net Earnings / Revenue
Basic Earnings Per Share -$0.32
Diluted Earnings Per Share -$316.4K -$0.32 -$379.1K
COMMON SHARES
Basic Shares Outstanding 12.79M shares 12.78M shares 11.06M shares
Diluted Shares Outstanding 12.78M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $27.67M $31.67M $45.26M
YoY Change -38.86% -14.03%
Cash & Equivalents $27.67M $31.67M $45.26M
Short-Term Investments
Other Short-Term Assets $230.0K $290.0K $770.0K
YoY Change -70.13% 16.0%
Inventory
Prepaid Expenses
Receivables $0.00
Other Receivables $0.00
Total Short-Term Assets $27.90M $31.95M $46.03M
YoY Change -39.4% -13.86% 741.28%
LONG-TERM ASSETS
Property, Plant & Equipment $73.78K $40.00K $28.79K
YoY Change 156.24% 14.82% -41.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $23.75K $20.00K $45.00K
YoY Change -47.22% -55.56% 0.0%
Total Long-Term Assets $97.54K $70.00K $73.79K
YoY Change 32.17% -12.32% -21.79%
TOTAL ASSETS
Total Short-Term Assets $27.90M $31.95M $46.03M
Total Long-Term Assets $97.54K $70.00K $73.79K
Total Assets $27.99M $32.02M $46.11M
YoY Change -39.29% -13.86% 728.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $306.3K $400.0K $1.027M
YoY Change -70.18% -73.03% 1080.12%
Accrued Expenses $1.327M $1.660M $256.8K
YoY Change 416.94% 1045.01% 137.85%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.634M $2.060M $1.284M
YoY Change 27.24% 26.51% 503.24%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.634M $2.060M $1.284M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $1.634M $2.060M $1.284M
YoY Change 27.24% 26.51% 413.46%
SHAREHOLDERS EQUITY
Retained Earnings -$68.24M -$47.86M
YoY Change 42.56% 28.41%
Common Stock $1.280K $1.267K
YoY Change 1.03% 184.08%
Preferred Stock
YoY Change
Treasury Stock (at cost) $40.71K $0.00
YoY Change
Treasury Stock Shares 5.710K shares 5.710K shares 0.000 shares
Shareholders Equity $26.36M $29.96M $44.82M
YoY Change
Total Liabilities & Shareholders Equity $27.99M $32.02M $46.11M
YoY Change -39.29% -13.86% 728.35%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q4
OPERATING ACTIVITIES
Net Income -$4.040M -$4.094M -$4.390M
YoY Change -7.97% 17.8%
Depreciation, Depletion And Amortization $0.00 $0.00 $0.00
YoY Change -100.0%
Cash From Operating Activities -$3.690M -$2.750M -$4.110M
YoY Change -10.22% -0.36% -297.6%
INVESTING ACTIVITIES
Capital Expenditures -$40.00K -$20.00K $0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities $0.00 $0.00
YoY Change
Cash From Investing Activities -$40.00K -$20.00K $0.00
YoY Change -100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -280.0K 280.0K 12.54M
YoY Change -102.23% -99.22% 31250.0%
NET CHANGE
Cash From Operating Activities -3.690M -2.750M -4.110M
Cash From Investing Activities -40.00K -20.00K 0.000
Cash From Financing Activities -280.0K 280.0K 12.54M
Net Change In Cash -4.010M -2.490M 8.430M
YoY Change -147.57% -107.49% 295.77%
FREE CASH FLOW
Cash From Operating Activities -$3.690M -$2.750M -$4.110M
Capital Expenditures -$40.00K -$20.00K $0.00
Free Cash Flow -$3.650M -$2.730M -$4.110M
YoY Change -11.19% -1.09%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
35981030 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
3761 shares
CY2013Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
8914666 shares
CY2013Q4 us-gaap Assets Current
AssetsCurrent
46033728 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
28794 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
45000 USD
CY2013Q4 us-gaap Assets
Assets
46107522 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1027021 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
256754 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
1283775 USD
CY2013Q4 us-gaap Treasury Stock Value
TreasuryStockValue
0 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-47864401 USD
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
44823747 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
46107522 USD
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3475339 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4094052 USD
CY2013Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.39
CY2014Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.32
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-3475339 USD
CY2014Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4094052 USD
CY2013Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
8914666 shares
CY2014Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
12775324 shares
CY2013Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.39
CY2014Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.32
CY2013Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
1933480 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
71260 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
285756 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
294373 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
303119 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
51903 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
1006411 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
267000 USD
us-gaap Lease And Rental Expense
LeaseAndRentalExpense
251000 USD
CY2013Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
89000 USD
CY2014Q3 us-gaap Lease And Rental Expense
LeaseAndRentalExpense
73000 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
758767 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1453897 USD
CY2013Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
160281 USD
CY2014Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
239771 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M13D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0175 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0 pure
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.7617 pure
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1264345 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
331689 shares
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
20205 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
3621 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1112 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1571096 shares
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1073897 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
3.25
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
8.30
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
2.81
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
5.73
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
12.84
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.31
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.88
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1028796 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1019409 USD
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12784382 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
12668393 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12778672 shares
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
12668393 shares
CY2014Q3 us-gaap Treasury Stock Shares
TreasuryStockShares
5710 shares
CY2013Q4 us-gaap Treasury Stock Shares
TreasuryStockShares
0 shares
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M20D
CY2014Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3695692 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y5M1D
CY2014Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
3475891 USD
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
2.06
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.48
CY2014Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2100000 USD
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
160000 USD
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
240000 USD
CY2013Q3 lpcn Percentage Of Fee To Be Received
PercentageOfFeeToBeReceived
0.2 pure
CY2013Q3 lpcn Maximum Proceeds From Affiliates Under License Agreement
MaximumProceedsFromAffiliatesUnderLicenseAgreement
10000000 USD
CY2013Q3 lpcn Description Of Terms Of Service Agreement
DescriptionOfTermsOfServiceAgreement
Under the service agreement, the Company will provide facilities and up to 10 percent of the services of certain employees to Spriaso for a period of up to 12 months with an ability to extend for another six months. On July 23, 2014, Spriaso notified the Company of its intention of extending the service agreement for another six months
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2657936 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12589355 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1568969 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3246526 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2601557 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3831181 USD
CY2013Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1181894 USD
CY2014Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
871825 USD
lpcn Reverse Merger Costs
ReverseMergerCosts
1011630 USD
lpcn Reverse Merger Costs
ReverseMergerCosts
0 USD
CY2013Q3 lpcn Reverse Merger Costs
ReverseMergerCosts
794902 USD
CY2014Q3 lpcn Reverse Merger Costs
ReverseMergerCosts
0 USD
us-gaap Operating Expenses
OperatingExpenses
6271123 USD
us-gaap Operating Expenses
OperatingExpenses
16420536 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
3545765 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
4118351 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-6271123 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-16420536 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-3545765 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4118351 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
16295 USD
us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
87700 USD
CY2013Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
15084 USD
CY2014Q3 us-gaap Other Operating Income Expense Net
OtherOperatingIncomeExpenseNet
24299 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-6254828 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-16332836 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-3530681 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4094052 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-55048 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-55342 USD
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 USD
us-gaap Net Income Loss
NetIncomeLoss
-6199780 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16332836 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3475339 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4094052 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
15725 USD
us-gaap Depreciation And Amortization
DepreciationAndAmortization
9387 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
3815 USD
us-gaap Other Noncash Expense
OtherNoncashExpense
0 USD
us-gaap Share Based Compensation
ShareBasedCompensation
758767 USD
us-gaap Net Income Loss
NetIncomeLoss
-16332836 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-3475339 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-4094052 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6199780 USD
us-gaap Share Based Compensation
ShareBasedCompensation
1453897 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
160815 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-484114 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1124921 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-627908 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
37027 USD
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1401034 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
-55048 USD
us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
0 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-4475388 USD
us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-13612312 USD
us-gaap Payments For Deposits
PaymentsForDeposits
0 USD
us-gaap Payments For Deposits
PaymentsForDeposits
-21247 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1206 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21280 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-1206 USD
us-gaap Net Cash Provided By Used In Investing Activities Continuing Operations
NetCashProvidedByUsedInInvestingActivitiesContinuingOperations
-33 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
53100 USD
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
10576 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
16064 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
35938506 USD
us-gaap Net Cash Provided By Used In Financing Activities Continuing Operations
NetCashProvidedByUsedInFinancingActivitiesContinuingOperations
16064 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
31461912 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-13596281 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5377114 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36839026 USD
us-gaap Noninterest Expense Offering Cost
NoninterestExpenseOfferingCost
271386 USD
us-gaap Noninterest Expense Offering Cost
NoninterestExpenseOfferingCost
0 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
0 USD
us-gaap Treasury Stock Value Acquired Cost Method
TreasuryStockValueAcquiredCostMethod
40712 USD
dei Document Type
DocumentType
10-Q
dei Amendment Flag
AmendmentFlag
false
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
12786672 shares
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Entity Registrant Name
EntityRegistrantName
Lipocine Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001535955
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Filer Category
EntityFilerCategory
Smaller Reporting Company
dei Trading Symbol
TradingSymbol
LPCN

Files In Submission

Name View Source Status
0001144204-14-066218-index-headers.html Edgar Link pending
0001144204-14-066218-index.html Edgar Link pending
0001144204-14-066218.txt Edgar Link pending
0001144204-14-066218-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
lpcn-20140930.xml Edgar Link completed
lpcn-20140930.xsd Edgar Link pending
lpcn-20140930_cal.xml Edgar Link unprocessable
lpcn-20140930_def.xml Edgar Link unprocessable
lpcn-20140930_lab.xml Edgar Link unprocessable
lpcn-20140930_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
v392036_10q.htm Edgar Link pending
v392036_ex31-1.htm Edgar Link pending
v392036_ex31-2.htm Edgar Link pending
v392036_ex32-1.htm Edgar Link pending
v392036_ex32-2.htm Edgar Link pending